Table 1, Submitted for Review - Clinical Review Report: Halobetasol Propionate and Tazarotene (Duobrii)

Item	Description
Drug product	Halobetasol propionate (0.01% w/w) and tazarotene (0.045% w/w) lotion (Duobrii) topical antipsoriatic agent
Indication	Improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis
Reimbursement request	As per indication
Health Canada approval status	NOC
Health Canada review pathway	Standard
NOC date	June 9, 2020
Sponsor	Bausch Health, Canada Inc.

Cover of Clinical Review Report: Halobetasol Propionate and Tazarotene (Duobrii)

Clinical Review Report: Halobetasol Propionate and Tazarotene (Duobrii): (Bausch Health, Canada Inc.): Indication: Psoriasis, moderate-to-severe plaque [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 1Submitted for Review